HUMA
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Humacyte announces acceptance of Phase 3 V012 trial results for ATEV in women requiring hemodialysis access for a late-breaking presentation at ASN Kidney Week 2026Oct 12, 2026
- FDA authorized Humacyte to extend Symvess shelf life to 36 monthsSep 9, 2026
- Humacyte confirmed plans to submit a supplemental BLA for ATEV as a dialysis access treatment following discussions with the FDAAug 24, 2026
- Humacyte announced publication in The Lancet Digital Health of results from the Phase 3 V007 hemodialysis access trialAug 19, 2026
- Humacyte receives FDA acceptance of IND for first-in-human study of CTEV in coronary bypass surgeryJul 27, 2026